Emily Feneberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/433299/publications.pdf Version: 2024-02-01



FMILY FENEREDC

#	Article	IF	CITATIONS
1	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 68-74.	0.9	39
2	Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Communications, 2022, 4, fcac029.	1.5	29
3	SARS-CoV-2 and neurodegenerative diseases: what we know and what we don't. Journal of Neural Transmission, 2022, 129, 1155-1167.	1.4	19
4	Detection and quantification of novel Câ€ŧerminal TDPâ€43 fragments in ALSâ€TDP. Brain Pathology, 2021, 31, e12923.	2.1	26
5	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.1	14
6	Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis. Expert Review of Proteomics, 2021, 18, 977-994.	1.3	5
7	An ALS-linked mutation in TDP-43 disrupts normal protein interactions in the motor neuron response to oxidative stress. Neurobiology of Disease, 2020, 144, 105050.	2.1	30
8	Amyotrophic lateral sclerosis with a heterozygous D91A SOD1 variant and classical ALS-TDP neuropathology. Neurology, 2020, 95, 595-596.	1.5	9
9	Hibernation Impairs Odor Discrimination – Implications for Alzheimer's Disease. Frontiers in Neuroanatomy, 2019, 13, 69.	0.9	5
10	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 157-164.	0.9	174
11	Towards a TDP-43-Based Biomarker for ALS and FTLD. Molecular Neurobiology, 2018, 55, 7789-7801.	1.9	100
12	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.5	148
13	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	0.9	89
14	Initial Identification of a Blood-Based Chromosome Conformation Signature for Aiding in the Diagnosis of Amyotrophic Lateral Sclerosis. EBioMedicine, 2018, 33, 169-184.	2.7	17
15	Amyotrophic lateral sclerosis: the complex path to precision medicine. Journal of Neurology, 2018, 265, 2454-2462.	1.8	36
16	Polyâ€ <scp>GP</scp> in cerebrospinal fluid links <i>C9orf72</i> â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp> / <scp>FTD</scp> . EMBO Molecular Medicine, 2017, 9, 859-868.	3.3	90
17	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-311387.	0.9	207
18	Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. Journal of Neurochemistry, 2016, 138, 184-192.	2.1	26

EMILY FENEBERG

#	Article	IF	CITATIONS
19	Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. Journal of Neural Transmission, 2016, 123, 289-296.	1.4	26
20	Prolactin Serum Concentrations After Electroconvulsive Therapy in a Depressed Patient With Cabergoline-Treated Prolactinoma. Journal of ECT, 2015, 31, e28-e29.	0.3	0
21	Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 757-768.	1.1	21
22	Intact Protein Analysis of Ubiquitin in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Differences in Alzheimer's Disease and Frontotemporal Lobar Degeneration. Journal of Proteome Research, 2014, 13, 4518-4525.	1.8	41
23	Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 351-356.	1.1	131
24	Influence of the blood-CSF-barrier function on S100B in neurodegenerative diseases. Acta Neurologica Scandinavica, 2013, 128, 249-256.	1.0	9
25	Elevated glial fibrillary acidic protein levels in the cerebrospinal fluid of patients with narcolepsy. Sleep Medicine, 2013, 14, 692-694.	0.8	13
26	Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische AnsĀæe in der Diagnose der Frontotemporalen LobĀædegeneration. Laboratoriums Medizin, 2012, 36, .	0.1	1